



ADVIK LABORATORIES LIMITED

Regd. Off. : 138, Roz Ka Meo Industrial Area, Sohna, Distt. Mewat Haryana - 122103

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER & HALF YEAR ENDED SEPTEMBER 30, 2016

CIN : L74899HR1994PLC038300

Sno.	Particulars	Quarter ended 30.09.2016 (Unaudited)	Quarter ended 30.06.2016 (Unaudited)	Quarter ended 30.09.2015 (Unaudited)	Year to date figures for the current period ended 30.09.2016	Year to date figures for the current period ended 30.09.2015	(Rs. in lacs) Previous Year ended 31.03.2016 (Audited)
1	Income from Operations						
	a. Net Sales/ Income from operation (Net of excise duty)	72.02	29.69	21.63	101.71	239.26	26.54
	b. Other Operating Income	10.61	18.93	-	29.54	-	108.93
	Total Income from Operations (net)	82.63	48.62	21.63	131.25	239.26	135.47
2	Expenses						
	a. Cost of material consumed	41.00	30.16	1.62	71.16	2.03	42.78
	b. Purchase of Stock in Trade	-	-	-	-	205.47	-
	c. Changes in inventories of finished goods, work in progress & stock in trade	23.84	378.17	0.88	402.01	0.88	(1.43)
	d. Employee benefits expense	17.92	18.47	21.55	36.39	40.14	78.08
	e. Depreciation & amortisation expenses	14.79	14.72	14.85	29.51	31.17	62.49
	(f) Other expenses (Any item exceeding 10% of the total expenses relating to continuing operations to be shown separately)	15.34	14.03	18.86	29.37	27.90	65.35
	Total Expenses	112.89	455.55	57.76	568.44	307.59	247.27
3	Profit/(Loss) from operations before other income, Finance Costs and Exceptional Items(1-2)	(30.26)	(406.93)	(36.13)	(437.19)	(68.33)	(111.80)
4	Other Income	-	0.80	-	0.80	0.04	0.35
5	Profit/(Loss) from ordinary activities before finance costs & exceptional items(3+4)	(30.26)	(406.13)	(36.13)	(436.39)	(68.29)	(111.45)
6	Finance Costs	0.02	0.03	0.05	0.05	27.19	8.22
7	Profit/(Loss) from ordinary activities after finance costs but before exceptional items(5-6)	(30.28)	(406.16)	(36.18)	(436.44)	(95.48)	(119.67)
8	Exceptional Items	-	-	-	-	-	-
9	Profit/(Loss) from Ordinary Activities before tax (7+8)	(30.28)	(406.16)	(36.18)	(436.44)	(95.48)	(119.67)
10	Tax Expense	-	-	-	-	-	(0.66)
11	Net Profit/Loss from Ordinary Activities after Tax (9-10)	(30.28)	(406.16)	(36.18)	(436.44)	(95.48)	(119.01)
12	Extra ordinary Items (net of tax)	-	-	-	-	-	-
13	Net Profit / (Loss) after taxes but before share of profit / (loss) of associates and minority interest (11+12)	(30.28)	(406.16)	(36.18)	(436.44)	(95.48)	(119.01)
14	Share of Profit/(Loss) of Associates	-	-	-	-	-	-
15	Minority Interest	-	-	-	-	-	-
16	Net Profit / (Loss) after taxes, minority interest and share of profit / (loss) of associates (13 + 14 + 15)	(30.28)	(406.16)	(36.18)	(436.44)	(95.48)	(119.01)
17	Paid up Equity Share Capital (Rs. 10/- per share)	1,911.14	1,911.14	1,911.14	1,911.14	1,911.14	1,911.14
18	Reserve excluding revaluation reserves as per balance sheet of previous accounting year	-	-	-	-	-	(12.85)
19	Earning per share (before extra ordinary items) of Rs. 10/- per share. (not annualised)						
	a) Basic	(0.158)	(2.125)	(0.189)	(2.284)	(0.500)	(0.623)
	b) Diluted	(0.158)	(2.125)	(0.189)	(2.284)	(0.500)	(0.623)
20	Earning per share (after extra ordinary items) of Rs. 10/- per share. (not annualised)						
	a) Basic	(0.158)	(2.125)	(0.189)	(2.284)	(0.500)	(0.623)
	b) Diluted	(0.158)	(2.125)	(0.189)	(2.284)	(0.500)	(0.623)

For and on behalf of Board of Directors of
Advik Laboratories Limited

(Peeyush Kumar Aggarwal)

Chairman

DIN : 00090423

Statement of Assets & Liabilities as on September 30, 2016

(Rs. In lacs)

Particulars		As at 30.09.16 (Unaudited)	As at 31.03.16 (Audited)
A.	EQUITY & LIABILITIES		
1	Shareholder's Funds		
	(a) Share Capital	1,911.14	1,911.14
	(b) Reserve and Surplus	(449.28)	(12.85)
	Sub-total-Shareholder's funds	1,461.86	1,898.29
2	Non-Current Liabilities		
	(a) Long Term borrowings	48.58	97.60
	(b) Deferred tax liabilities (Net)	98.00	98.00
	(c) Other long term liabilities	-	-
	(d) Long Term Provisions	18.42	18.42
	Sub-total-Non Current Liabilities	165.00	214.02
3	Current Liabilities		
	(a) Short term borrowings	310.08	289.52
	(b) Trade payables	59.32	64.41
	(c) Other current liabilities	443.98	391.10
	(d) Short Term provisions	-	-
	Sub-total Current Liabilities	813.38	745.03
	TOTAL EQUITY & LIABILITIES	2,440.24	2,857.34
B.	ASSETS		
1	Non Current Assets		
	(a) Fixed Assets	1,350.03	1,378.71
	(b) Non Current Investments	92.30	92.30
	Sub-total-Non current assets	1,442.33	1,471.01
2	Current Assets		
	(a) Inventories	349.82	753.10
	(b) Trade receivables	424.34	427.19
	(c) Cash & cash equivalents	16.91	3.12
	(d) Short term loan and advances	206.51	202.52
	(e) Other current assets	0.33	0.40
	Sub-total Current Assets	997.91	1,386.33
	TOTAL ASSETS	2,440.24	2,857.34

Notes :

- 1 The above financial results have been reviewed by the Audit Committee & approve by the Board of Directors in the meeting held on November 14, 2016.
- 2 The Statutory Auditors have carried out the "Limited Review" of the Standalone financial results of the Company for the quarter ended September 30, 2016 in accordance with regulation 33 of the SEBI (LODR) Regulations, 2015.
- 3 The statement of unaudited financial results for the quarter and half year ended 30th September, 2016 has been prepared following the same accounting policies as were followed in the annual financial statement for the year ended 31st March, 2016.
- 4 The Company is engaged in pharmaceuticals business only & therefore, there is only one reportable segment as per AS-17 issued by the ICAI.
- 5 No investor complaint was pending as on 30th September, 2016 and no complaint was received during the quarter under review.
- 6 Previous year/period figures have been regrouped/rearranged, wherever necessary to make them comparable with the current period figure.

Place: New Delhi

Date : 14th November, 2016



For and on behalf of Board of Directors of
Advik Laboratories Limited

(Peeyush Kumar Aggarwal)

Chairman

DIN : 00090423